Etafa - instructions for use, reviews, analogs and formulations (tablets 0.25 μg and 1 μg, injections in ampoules for injections of 0.5 ml and 1 ml, drops of 20 ml) of the drug for the treatment of rickets, osteoporosis in adults, children and during pregnancy. Composition

In this article, you can read the instructions for using the drugEthaf. Presented are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Etipla in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues Etalphs in the presence of existing structural analogues. Use for the treatment of rickets, osteoporosis, lack of calcium, hypoparathyroidism in adults, children, as well as during pregnancy and lactation. Composition of the preparation.

Ethaf - increases the absorption of calcium and phosphorus in the intestines, increases their reabsorption in the kidneys, enhances the mineralization of bones, reduces the content of parathyroid hormone in the blood. The main advantages of alfacalcidol (active ingredient of the drug Etagol) in comparison with vitamin D - rapid action and the possibility of more precise dose adjustment, which reduces the risk of prolonged hypercalcemia.

Composition

Alfacalcidol + excipients.

Pharmacokinetics

The preparation is fat-soluble, bioavailability when ingested is 100%. After absorption, it rapidly turns into 1,25-dihydroxyvitamin D3, mainly in the liver. The level of 1,25-dihydroxyvitamin D3 in blood plasma reaches a maximum after 8-12 hours after taking a single dose of alfacalcidol. The half-life of 1,25-dihydroxyvitamin D3 is about 35 hours.

Indications

Diseases caused by impaired calcium and phosphorus metabolism due to insufficient endogenous production of 1,25-dihydroxyvitamin D3:

• renal osteodystrophy;
• osteoporosis;
• postoperative or idiopathic hypoparathyroidism;
• pseudohypoparathyroidism;
• hypoparathyroidism with bone damage;
• vitamin D-resistant rickets or osteomalacia;
• vitamin D-dependent rickets;
• hypocalcemia or rickets of newborns;
• calcium malabsorption;
• rickets associated with malabsorption and malnutrition;
• osteomalacia.

Forms of release

Tablets or capsules 0.25 μg and 1 μg.

Injections in ampoules for injections and intravenous infusions of 0.5 ml and 1 ml.

Drops for oral administration 20 ml.

Instructions for use and dosing regimen

Inside or intravenously once a day.

Ampoules must be shaken several times before use, do not dilute the drops. Begin treatment with minimal doses, controlling once a week the level of calcium and phosphorus in the blood plasma. The dose of the drug can be increased by 0.25 or 0.5 μg per day until the biochemical parameters stabilize. When the minimum effective dose is reached, it is recommended to monitor the level of calcium in the blood plasma every 3-5 weeks. The duration of the course is determined by the doctor individually in each case and depends on the nature of the disease and the effectiveness of therapy. In some cases, the drug is used for life.

Adults with osteomalacia appoint inwards at a dose of 1-3 mcg per day.

When hypoparathyroidism - 2-4 mcg per day.

In osteodystrophy in chronic renal failure - up to 2 mcg per day.

At postmenopauznom, senile, steroid and other types of osteoporosis - 0.5-1 mcg per day.

The drug can be administered intravenously after hemodialysis. The injection should be performed in the return line of the device (as close to the patient as possible - to eliminate the risk of absorption of alfacalcidol by the plastic) at the end of each dialysis. The initial dose is 1, the maximum dose is 6 μg for dialysis, but not more than 12 μg for a week. The solution does not require additional dilution.

With a body weight of less than 20 kg - 0.01-0.05 μg per kilogram per day, with a mass of 20 kg and above - 1 μg per day (except for cases of renal osteodystrophy).

In renal osteodystrophy in children, the dose is 0.04-0.08 μg per kilogram per day. The dose is determined in accordance with the dynamics of biochemical indicators in order to prevent hypercalcemia.

Side effect

• hypercalcemia (increased concentration of calcium in the blood plasma);
• hyperphosphataemia (high phosphate content);
• nausea;
• dry mouth;
• a feeling of discomfort in the epigastric region (abdominal pain);
• constipation;
• weakness, fatigue;
• dizziness;
• drowsiness;
• tachycardia;
• skin rash;
• itching.

Contraindications

• hypersensitivity to the components of the drug;
• hypercalcemia;
• hyperphosphataemia (except for those with hypoparathyroidism);
• hypermagnesia;
• intoxication with vitamin D.

A solution for intravenous administration should not be used in patients with increased sensitivity to injection solutions containing propylene glycol.

Application in pregnancy and lactation

There is no clinical experience of use in pregnancy and lactation, so Etago can be prescribed only when this therapy is needed.

Use in children

Young children are recommended to prescribe the drug in the dosage form of the drop (dosing and taking capsules are difficult).

special instructions

Caution should be given to patients prone to hypercalcemia, especially in the presence of urolithiasis.

In the treatment, the determination of biochemical parameters (measurement of serum calcium, alkaline phosphatase, parathyroid hormone, amount of calcium excreted in the urine), as well as radiographic and histological studies should be regularly performed.

Control frequency: the calcium content in the blood plasma should be determined at an interval of 1 week to 1 month, depending on the patient's condition. Frequent measurements are necessary in the early stages of treatment (especially with an initially high level of calcium in the plasma) and later, when there are signs of normalization of bone structure, as well as in diseases without significant damage to bones, for example, in hypoparathyroidism.

With the development of hypercalcemia, treatment with the drug should be stopped immediately, until the serum calcium level is normalized (usually within a week). Then the treatment is continued, starting at half the last dose. The risk of developing hypercalcemia depends on factors such as the degree of demineralization, the function of the kidneys and the dose of the drug. Hypercalcemia develops if the dose of alfacalcidol is not reduced when biochemical signs of bone structure normalization appear (for example, when the serum level of serum is normalized). Long-term hypercalcemia should be avoided, especially in chronic kidney failure.

Patients with renal osteodystrophy Ethaph can be administered in combination with phosphate binding agents,to prevent hyperphosphataemia.

Solution for injection should be used with caution in preterm infants.

Drops for oral administration can not be diluted.

Drug Interactions

With simultaneous use with digitalis preparations, the risk of heart rhythm disturbances increases; with antacids - the risk of hypermagnesemia; with calcium preparations and thiazide diuretics - the risk of hypercalcemia.

Joint use with barbiturates, anticonvulsants and other drugs that activate enzymes of microsomal oxidation in the liver, requires the use of a higher dose of etalphs.

Mineral oil (when used together for a long time), cholestyramine, colestipol, sucralfate, antacids, albumin, alfacalcidol drugs reduce the absorption.

Analogues of the drug Etagolf

Structural analogs for the active substance:

• Alfadol;
• Van Alpha;
• Oxidevit.

Analogues on the pharmacological group (correctors of bone and cartilage tissue metabolism):

• Adelon;
• Aklast;
• Actonel;
• Alendercourne;
• Alendronate;
• Aminoarthrin;
• Heredia;
• Artogistan;
• Artradol;
• Arthrakam;
• Arthrin;
• Biartrin;
• Bivalos;
• Blazter;
• Bonviva;
• Bondronate;
• Bonefos;
• Veprena;
• Veroclast;
• Videchol;
• Gialgan;
• Glucosamine;
• Dihydrotachysterol;
• Zemplar;
• Zoledronate;
• Zoledrax;
• Zolerix;
• Calcitonin;
• Cartilag;
• Klobir;
• Complivit;
• Xidifon;
• Mukosat;
• Ostalon;
• Osteover;
• Osteolate;
• Osteotriol;
• Osteohin;
• Piascladed;
• Resoclastine;
• Risendros;
• Rockaltrol;
• Rumalon;
• Sinoarth;
• Skelid;
• Stringos;
• Structum;
• Soustagard;
• Tazan;
• Tahistin;
• Tevanath;
• Tridin;
• Fitin;
• Fosamax;
• Chondraktiv;
• Chondramine;
• Hondrogaard;
• Chondroitin;
• Chondroxide;
• Chondrolon;
• Honsurid;
• Exidgiva;
• Elbon;
• The Unium.

Review of the endocrinologist

Ethal is an effective drug for the treatment of pathologies that develop as a result of a violation of calcium and phosphorus metabolism in the body. The active substance of the drug alfacalcidol improves the absorption of calcium and phosphorus in the intestine, enhances the absorption of these substances by the kidneys, promotes the mineralization of bones, while the level of parathyroid hormone in the blood decreases. Ethal, compared with conventional vitamin D, has one significant advantage - it works faster and allows you to more accurately adjust the dose, which reduces the risk of hypercalcemia (the main side effect of drug treatment).

Similar medicines:

Other medicines: